UpToDate Contents
全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.
- 1. 肝疾患を有する患者における化学療法による肝毒性および用量調整 chemotherapy hepatotoxicity and dose modification in patients with liver disease
- 2. 抵抗性または再発性の妊娠性絨毛腫瘍のマネージメント management of resistant or recurrent gestational trophoblastic neoplasia
- 3. 切除可能大腸癌の肝転移のマネージメント management of potentially resectable colorectal cancer liver metastases
- 4. 大腸癌の肝転移に対する非外科的局所治療戦略 nonsurgical local treatment strategies for colorectal cancer liver metastases
- 5. 切除III期（リンパ節陽性）結腸癌に対する補助化学療法 adjuvant therapy for resected stage iii node positive colon cancer
English Journal
- Ten-year outcomes of a randomised trial for locoregionally advanced nasopharyngeal carcinoma: A single-institution experience from an endemic area.
- Huang PY1, Zeng Q2, Cao KJ1, Guo X1, Guo L1, Mo HY1, Wu PH2, Qian CN1, Mai HQ3, Hong MH4.
- European journal of cancer (Oxford, England : 1990).Eur J Cancer.2015 Sep;51(13):1760-70. doi: 10.1016/j.ejca.2015.05.025. Epub 2015 Jun 17.
- OBJECTIVE: We previously reported the five-year results of a randomised trial that compared induction chemotherapy plus concurrent chemoradiotherapy (IC+CCRT) with induction chemotherapy plus radiotherapy (IC+RT) in patients with locoregionally advanced nasopharyngeal carcinoma (NPC). The aim of thi
- PMID 26093812
- Genotype-phenotype correlations in 5-fluorouracil metabolism: a candidate DPYD haplotype to improve toxicity prediction.
- Gentile G1, Botticelli A2, Lionetto L3, Mazzuca F4, Simmaco M1, Marchetti P4, Borro M1.
- The pharmacogenomics journal.Pharmacogenomics J.2015 Jul 28. doi: 10.1038/tpj.2015.56. [Epub ahead of print]
- 5-Fluorouracil is among the most widely used anticancer drug, but a fraction of treated patients develop severe toxicity, with potentially lethal injuries. The predictive power of the available pretreatment assays, used to identify patients at risk of severe toxicity, needs improvements. This study
- PMID 26216193
- Self-Assembled Nanoparticles of Amphiphilic Twin Drug from Floxuridine and Bendamustine for Cancer Therapy.
- Zhang T1, Huang P1, Shi L1, Su Y1, Zhou L1, Zhu X1, Yan D1.
- Molecular pharmaceutics.Mol Pharm.2015 Jul 6;12(7):2328-36. doi: 10.1021/acs.molpharmaceut.5b00005. Epub 2015 Jun 3.
- We report here an amphiphilic twin drug strategy directly using small molecular hydrophilic and hydrophobic anticancer drugs to self-assemble into nanoparticles with a high and fixed drug content, which can solve problems of anticancer drug delivery including poor water solubility, low therapeutic i
- PMID 25996874
Japanese Journal
- 先天性胆道閉鎖症 I cyst 型に肝細胞癌を合併した1例
- 田村 元,秦 温信,佐々木 文章,高橋 弘昌,浜田 弘巳,内野 純一,中沢 修,美馬 聡昭,安念 和哉,藤岡 保範
- 日本小児外科学会雑誌 29(1), 131-135, 1993-02-20
- … 5'FUDR を投与したが,発症5ヵ月後 DIC にて死亡した.本症は HCC の合併まで黄疸を認めなかった初めての症例と思われた. …
- NAID 110002104047
- Controlled Release of 5-Fluoro-2'-deoxyuridine by the Combination of Prodrug and Polymer Matrix
- 遠藤 浩孝,川口 健夫,関 俊暢,長谷川 哲也,從二 和彦
- Chemical & pharmaceutical bulletin 39(2), 458-464, 1991-02-25
- … Poly(L-lactic acid) (L-PLA) microspheres containing 5-fluoro-2'-deoxyuridine (FUdR) or its ester prodrugs with saturated aliphatic acids (FUdR-Cn, n=2,3,4,5,6,8,10 and 12) were prepared. … The lipophilicity of FUdR-Cn was increased by prolonging its acyl-promoieties. …
- NAID 110003629137
- Controlled Release of 5-Fluoro-2'-deoxyuridine by the Combination of Prodrug and Polymer Matrix
- 遠藤 浩孝,川口 健夫,関 俊暢,長谷川 哲也,從二 和彦
- Chemical and Pharmaceutical Bulletin 39(2), 458-464, 1991-02
- … Poly(L-lactic acid) (L-PLA) microspheres containing 5-fluoro-2'-deoxyuridine (FUdR) or its ester prodrugs with saturated aliphatic acids (FUdR-Cn, n=2, 3, 4, 5, 6, 8, 10 and 12) were prepared. … The lipophilicity of FUdR-Cn was increased by prolonging its acyl-promoieties. …
- NAID 120005404308
Related Pictures
★リンクテーブル★
| リンク元 | 「5-フルオロデオキシウリジン」 |
| 関連記事 | 「FU」「FUdR」 |
「5-フルオロデオキシウリジン」
- 抗悪性腫瘍薬